This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Medicis Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Medicis Pharmaceutical Corporation (MRX)

Q2 2012 Earnings Call

August 8, 2012 5:15 pm ET

Executives

Jonah Shacknai – Chairman and Chief Executive Officer

Mark A. Prygocki, Sr. – President

Richard D. Peterson – Executive Vice President, Chief Financial Officer and Treasurer

Analysts

Christopher T. Schott – JP Morgan Securities Inc.

Greg P. Waterman – Goldman Sachs & Co.

Gary Nachman – Susquehanna Financial Group LLP

Rebecca M. Forest – Piper Jaffray, Inc.

Daniel Chang – Stifel Nicolaus & Company, Inc.

Ken Cacciatore – Cowen and Company, LLC

Shibani Malhotra – RBC Capital Markets Equity Research

Ronny Gal – Sanford C. Bernstein & Co.

Catherine Arnold – Credit Suisse

Douglas D. Tsao – Barclays Capital, Inc.

David Risinger – Morgan Stanley

Stephen Barr Willoughby – Cleveland Research Co.

Presentation

Operator

Thank you for joining the Medicis Second Quarter 2012 Financial Results Conference Call. Today's call is being recorded and webcast live on the company's website at www.medicis.com in the Investor Relations section. And will be available for replay for 10 business days following this call.

This is a brief reminder that all discussions today include forward-looking statements. These statements are based on current assumptions made by Medicis based on historical trends, current conditions, expected future developments, and other factors the company believes appropriate today.

Factors may cause actual results to differ materially from those projected in forward-looking statements. You can find a discussion of these factors and more information about Medicis in the company's filings with the Securities and Exchange Commission. The assumptions underlying the forward-looking statements can change and Medicis disclaims any obligation to update those statements. Please note that references to non-GAAP figures in this webcast are reconciled to GAAP figures as noted in today's press release, which also can be found on the company's website at www.medicis.com.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,199.52 -14.90 -0.08%
S&P 500 2,109.96 -0.78 -0.04%
NASDAQ 4,982.3190 -5.5710 -0.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs